Reid Hoffman: Medical AI, the New Lucrative Eldorado

Reid Hoffman, co-founder of LinkedIn, recently highlighted the lucrative potential of artificial intelligence in the field of drug discovery. As a co-founder of the biopharmaceutical company Manas AI, Hoffman stated that AI could revolutionize this sector by accelerating the development of new treatments. According to him, companies that can leverage AI in medicine could benefit from highly lucrative monopoly opportunities.

During an episode of The Possible Podcast, Hoffman asserted that one of the greatest profit potentials of AI is often underestimated. He emphasized that the time has come for medicine to benefit from AI advancements, while noting that the revenue model of Anthropic fascinates many people. Hoffman pointed out that the total addressable market (TAM) for drugs is much larger than that of AI chatbots, where players like OpenAI and Anthropic already dominate.

The process of developing a drug is notoriously lengthy, often exceeding 10 years, especially if the drug successfully passes clinical trials. New York-based Manas AI uses AI models to make this process more efficient, optimizing early research before committing significant resources to research and development. Hoffman described Manas AI as a "drug discovery factory for monopolies," as drugs benefit from 20-year legal monopolies through patents.

Hoffman also mentioned that many AI startups have emerged in the biopharmaceutical sector since the COVID-19 pandemic, seeking to reduce the cost and time required to deliver medications to patients. He challenged the notion that a single player could dominate the market, citing the example of GLP1 drugs, where multiple suppliers generate revenues in the tens of billions of dollars.

In conclusion, Hoffman stated that it is entirely possible to have a monopoly on one drug while also having other drugs in the same field that can also be very lucrative. He encouraged companies to explore the possibilities offered by AI to discover and develop the next generation of drugs, raising the question of what new discoveries this technology could enable.